Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro

Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro


Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. 

Mike Blake | Reuters

Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.

The drugmaker now expects full-year adjusted earnings of $13.50 to $14.00 per share, up from a previous guidance of $12.20 to $12.70 per share. Eli Lilly also expects revenue for the year to come in between $42.4 billion and $43.6 billion, an increase of $2 billion at either end of the range.

Analysts surveyed by LSEG expected full-year adjusted earnings of $12.50 per share and sales of $41.44 billion. 

The results and guidance raise reflect Zepbound’s first full quarter on the U.S. market after winning approval from regulators in early November. The drug reported $517.4 million in sales for the first quarter, even as most doses of the drug slipped into shortages in the U.S. that are expected to last through June.

Analysts say the weekly injection could post more than a billion dollars in sales in its first year on the market and potentially become the biggest drug of all time.

Here’s what Eli Lilly reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: $2.58 adjusted vs. $2.46 expected
  • Revenue: $8.77 billion vs. $8.92 billion expected

Eli Lilly posted a net income of $2.24 billion, or $2.48 a share, for the first quarter. That compares with a profit of $1.34 billion, or $1.49 a share, a year earlier. 

Excluding one-time items associated with the value of intangible assets, among other adjustments, the company posted a per-share profit of $2.58 for the first quarter of 2024.

The pharmaceutical giant booked first-quarter revenue of $8.77 billion, up 26% year over year.

In February, Eli Lilly said it expects revenue growth to accelerate in the second half of the year, which will be consistent with the increased availability of incretin drug doses. Incretin drugs are treatments such as Mounjaro and Zepbound, which mimic hormones produced in the gut to suppress a person’s appetite and regulate their blood sugar.

Shares of Eli Lilly jumped almost 8% in premarket trading Tuesday. They’re up 26% this year after jumping almost 60% in 2023 due to the insatiable demand for the company’s weight loss and diabetes drugs. That’s despite their hefty price tags, spotty insurance coverage and intermittent supply shortages. 

With a market cap of about $700 billion, Eli Lilly is the largest pharmaceutical company based in the U.S. 

This story is developing. Please check back for updates.



Source

Healthy Returns: What to know about a CDC vaccine panel’s votes against a mercury preservative in flu shots
Health

Healthy Returns: What to know about a CDC vaccine panel’s votes against a mercury preservative in flu shots

Biostatistician and epidemiologist Martin Kulldorff, MD, PhD, and Dr. Mina Zadeh, ACIP Executive Secretary, CDC, look on as people present their information to members of the Advisory Committee on Immunization Practices, as the U.S. Centers for Disease Control and Prevention’s (CDC) advisory panel for vaccines convenes, in Atlanta, Georgia, U.S. June 25, 2025. Megan Varner […]

Read More
Medicaid cuts in Trump’s ‘big beautiful’ bill will leave millions uninsured, threaten rural hospitals
Health

Medicaid cuts in Trump’s ‘big beautiful’ bill will leave millions uninsured, threaten rural hospitals

An aerial view of Valley Health Hampshire Memorial Hospital on June 17, 2025 in Romney, W.V. Ricky Carioti | The Washington Post | Getty Images President Donald Trump’s “big, beautiful bill” would make sweeping changes to U.S. health care, leaving millions of vulnerable Americans without health insurance and threatening the hospitals and centers that provide […]

Read More
Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Health

Moderna’s flu vaccine shows positive late-stage trial results, paving way for combination Covid shot

The Moderna Inc. headquarters in Cambridge, Massachusetts, on March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and […]

Read More